Trial · NCT03443973
Results by group81
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 81
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB | Placebo: DBT | 3.01 | Standard Error 0.15 | score on a scale | |
| DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB | Gantenerumab: DBT | 2.82 | Standard Error 0.14 | score on a scale | |
| OLE Period: Number of Participants With Adverse Events (AEs) | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | 8 | Participants | ||
| OLE Period: Number of Participants With Adverse Events (AEs) | Gantenerumab (DBT) to Gantenerumab: OLE | 6 | Participants | ||
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | Suicidal Ideation: Passive | 1 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Gantenerumab (DBT) to Gantenerumab: OLE | Suicidal Ideation: Passive | 0 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | Suicidal Ideation: Active-Method, but no Intent or Plan | 1 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Gantenerumab (DBT) to Gantenerumab: OLE | Suicidal Ideation: Active-Method, but no Intent or Plan | 0 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | Suicidal Ideation: No Event | 10 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Gantenerumab (DBT) to Gantenerumab: OLE | Suicidal Ideation: No Event | 13 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | Suicidal Behavior: No event | 12 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Gantenerumab (DBT) to Gantenerumab: OLE | Suicidal Behavior: No event | 13 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | Self-injurious Behavior Without Suicidal Intent: No event | 12 | Participants | |
| OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) | Gantenerumab (DBT) to Gantenerumab: OLE | Self-injurious Behavior Without Suicidal Intent: No event | 13 | Participants | |
| OLE Period : Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | 2 | Participants | ||
| OLE Period : Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI | Gantenerumab (DBT) to Gantenerumab: OLE | 1 | Participants | ||
| OLE Period: Number of Participants With Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI) | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | 0 | Participants | ||
| OLE Period: Number of Participants With Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI) | Gantenerumab (DBT) to Gantenerumab: OLE | 1 | Participants | ||
| OLE Period: Number of Participants With Injection-Site Reactions | Placebo (DBT) to Gantenerumab: Open-label Extension (OLE) | 0 | Participants | ||
| OLE Period: Number of Participants With Injection-Site Reactions | Gantenerumab (DBT) to Gantenerumab: OLE | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03443973/results